首个副伤寒甲型沙门菌人类挑战模型的临床与微生物学反应评估
研究建立首个副伤寒甲型沙门菌人类挑战模型,两组各20名参与者经碳酸氢钠预处理后口服不同剂量(1-5×10^3 CFU和0.5-1×10^3 CFU)的副伤寒甲型沙门菌。1-5×10^3 CFU组攻击率达60%(12/20),亚临床菌血症发生率高(11/20,55%),菌血症中位持续时间53小时,提示该模型可用于疫苗效力评估。
要点
- 1-5×10^3 CFU剂量组攻击率60%,亚临床菌血症率55%。
- 菌血症中位持续53小时,抗生素治疗后仍可持续长达96小时。
- 模型耐受性良好,适用于以菌血症和/或症状为终点的疫苗评估。
核心结论
- 1-5×10^3 CFU副伤寒甲型沙门菌挑战耐受性良好且安全性可接受,模型适用于疫苗效力评估。
研究设计与样本
- 两组各20名参与者,经碳酸氢钠预处理后口服副伤寒甲型沙门菌,剂量分别为1-5×10^3 CFU和0.5-1×10^3 CFU。
- 门诊监测,每日临床评估并采集血液和粪便培养,达到预设诊断标准或挑战后第14天开始抗生素治疗。
主要发现
- 1-5×10^3 CFU组攻击率为12/20(60%),达到主要研究目标。
- 该剂量组亚临床菌血症发生率为11/20(55%)。
- 尽管症状有限,抗生素治疗后菌血症仍持续长达96小时,中位持续时间53小时(四分位距24-85小时)。
- 粪便排菌通常先于菌血症出现。
关键数值与推荐
- 预设诊断标准:体温≥38°C持续≥12小时和/或菌血症。
临床怎么用
- 该模型可用于评估副伤寒疫苗效力,终点包括菌血症和/或症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To expedite the evaluation of vaccines against paratyphoid fever, we aimed to develop the first human challenge model of Salmonella enterica serovar Paratyphi A infection. METHODS: Two groups of 20 participants underwent oral challenge with S. Paratyphi A following sodium bicarbonate pretreatment at 1 of 2 dose levels (group 1: 1-5 × 103 colony-forming units [CFU] and group 2: 0.5-1 × 103 CFU). Participants were monitored in an outpatient setting with daily clinical review and collection of blood and stool cultures. Antibiotic treatment was started when prespecified diagnostic criteria were met (temperature ≥38°C for ≥12 hours and/or bacteremia) or at day 14 postchallenge. RESULTS: The primary study objective was achieved following challenge with 1-5 × 103 CFU (group 1), which resulted in an attack rate of 12 of 20 (60%). Compared with typhoid challenge, paratyphoid was notable for high rates of subclinical bacteremia (at this dose, 11/20 [55%]). Despite limited symptoms, bacteremia persisted for up to 96 hours after antibiotic treatment (median duration of bacteremia, 53 hours [interquartile range, 24-85 hours]). Shedding of S. Paratyphi A in stool typically preceded onset of bacteremia. CONCLUSIONS: Challenge with S. Paratyphi A at a dose of 1-5 × 103 CFU was well tolerated and associated with an acceptable safety profile. The frequency and persistence of bacteremia in the absence of clinical symptoms was notable, and markedly different from that seen in previous typhoid challenge studies. We conclude that the paratyphoid challenge model is suitable for the assessment of vaccine efficacy using endpoints that include bacteremia and/or symptomatology. CLINICAL TRIALS REGISTRATION: NCT02100397.
引用
- Dobinson HC, Gibani MM, Jones C, et al. Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clin Infect Dis. 2017. PMID: 28158395. doi:10.1093/cid/cix042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。